Influenza-Triggered Seronegative Myasthenia Gravis in an Anaplastic Lymphoma Kinase-Positive Lung Cancer Patient on Chronic Alectinib: A Case Report.

INTRODUCTION

Seronegative myasthenia gravis is an under-recognized cause of acute neuromuscular respiratory failure, and its convergence with infection and targeted oncologic therapy, specifically anaplastic lymphoma kinase inhibition, is poorly characterized, underscoring the importance of vigilance in oncologic patients presenting with respiratory failure.

CASE PRESENTATION: A 51-year-old man with anaplastic lymphoma kinase-positive non-small-cell lung cancer on long-term alectinib presented with fever, cough, and progressive generalized weakness. He tested positive for influenza A and rapidly developed respiratory failure requiring intubation. Neurological examination demonstrated ptosis, oculobulbar involvement, and proximal weakness. Repetitive nerve stimulation showed a decremental response, while assays for acetylcholine receptor, anti-muscle-specific kinase, and anti-lipoprotein receptor-related protein 4 antibodies were negative. A diagnosis of seronegative myasthenia gravis was established. The patient received intravenous immunoglobulin, plasma exchange, pyridostigmine, corticosteroids, and azathioprine with gradual clinical improvement.

CONCLUSION

Early recognition of myasthenia gravis in this population is critical to initiate appropriate immunotherapy and supportive management. This case illustrates the difficulty of distinguishing underlying disease and treatment-related effects from new-onset neurological syndromes. It highlights the importance of neurological considerations in cases of progressive respiratory difficulty and posits a putative link between chronic immunosuppression and subsequent susceptibility to autoimmune insult, as well as the need for more aggressive treatment in the setting of immunosuppression.